Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Yutaka_Niihara
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:EndariApprovalYear |
2017
|
| gptkbp:EndariApprovedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:focusesOn |
rare diseases
sickle cell disease |
| gptkbp:foundedYear |
2000
|
| gptkbp:founder |
gptkb:Yutaka_Niihara
|
| gptkbp:headquartersLocation |
gptkb:Torrance,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Emmaus Life Sciences, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Endari
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:OTCQB
|
| gptkbp:stockSymbol |
gptkb:EMMA
|
| gptkbp:website |
https://www.emmausmedical.com/
|
| gptkbp:bfsParent |
gptkb:OTCQB:_EMMA
|
| gptkbp:bfsLayer |
7
|